Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A bispecific antibody for multiple myeloma and its application

A bispecific antibody and antibody technology, applied in the fields of antibody, application, fermentation, etc., can solve problems such as the complex structure of bispecific antibodies, and achieve the effect of enhancing the killing function

Active Publication Date: 2022-08-02
CHINA PHARM UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] But at the same time, bispecific antibodies are more complex in structure than monoclonal antibodies, and bispecific antibodies face greater challenges in the development of antibody drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A bispecific antibody for multiple myeloma and its application
  • A bispecific antibody for multiple myeloma and its application
  • A bispecific antibody for multiple myeloma and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Construction of bispecific antibody DF00.

[0036] First, the BCMA-targeting single-chain antibody 2A9 and the PD-1-targeting antibody D00, which were screened by the laboratory through phage display technology and optimized by the company, were used as templates to design primers to retrieve the heavy and light chain variable region genes. The IgG4 constant region (Fc segment is mutated by knobs-into-holes, Fab segment is modified by Crossover) gene is used as a template to design primers to retrieve the heavy and light chain constant region genes, and the variable regions and constant regions of the heavy and light chains are respectively passed through overlap PCR technology The heavy and light chain genes of bispecific antibody DF00 were constructed by ligation; the obtained PCR product and pCMV3 vector were double digested with EcoRI and NotI respectively, and after recovering the target fragment and double digested vector, T4 DNA ligase was ligated at 16 ...

Embodiment 2

[0037] Example 2 Expression, purification and identification of bispecific antibody DF00.

[0038] First, the four recombinant plasmids pCMV3-F00-H / L-Chain (knob end) and pCMV3-D00-H / L-Chain (hole end) were transfected into HEK293 cells by PEI transfection reagent in a certain proportion. The medium was changed daily and the cells were passaged, and the scale of cell fermentation was gradually expanded. The cell culture medium was collected, and the samples were filtered with a 0.22 μm filter membrane and then purified by ProteinA column affinity chromatography to obtain a large amount of the target protein. 8% non-reducing and 12% reducing SDS-PAGE electrophoresis were performed respectively, and the molecular weight and assembly were identified by Western blotting, and the target protein was preliminarily verified. see the results figure 2 , F00 and DF00 were successfully expressed and assembled correctly.

Embodiment 3

[0039] Example 3 The binding affinity of DF00 to BCMA and PD-1 was verified by ELISA analysis.

[0040]The antigens BCMA and PD-1 were first mixed with 50mM NAHCO 3 The buffer was diluted to 1 μg / ml and coated on the activated ELISA plate overnight at 4°C; after washing with PBS to remove the antigen not bound to the ELISA plate, 5% skim milk was blocked at 37°C for 2h; the plate was washed again with PBST Then start to incubate a series of diluted antibodies (500nM-0.244nM / 250nM-0.122nM) at 37°C for 2h; then wash the plate with PBST again, wash away the antibodies that are not bound to the antigen, and use HRP-labeled goat antibody Human IgG (H+L) was incubated at 37°C for 2h; after washing the plate with PBST, the color was developed with TMB chromogenic solution. When there was an obvious color gradient, the reaction was terminated with 2M dilute sulfuric acid, and the OD was detected by a microplate reader. 450 -OD 630 value as the final result. see the results image ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a bispecific antibody for multiple myeloma and its application, and belongs to the technical field of genetic engineering antibodies. In the present invention, the antibody F00 targeting human BCMA and the antibody D00 targeting human PD-1 are used as parent antibodies, and 'knob' and 'hole' ends are respectively introduced into the two heavy chain Fc according to the CrossMab platform using genetic engineering technology. Animal eukaryotic expression system expresses DF00. The present invention also provides a method for expressing and purifying the bispecific antibody DF00. The target protein is obtained by secreting expression of HEK293 cells and purifying by affinity chromatography. The bispecific antibody DF00 can specifically bind to both the BCMA molecule on the surface of multiple myeloma (MM) cells and the immune checkpoint molecule PD-1 on the surface of activated T cells, inhibiting the immunosuppressive microenvironment in tumors and promoting T cells Recruited to surrounding multiple myeloma cells, remodeling the function of T cells to kill MM cells.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering antibodies, in particular to a novel antibody that can simultaneously target human B-cell maturation antigen (BCMA) and the immunosuppressive molecule programmed cell death protein 1 (PD). -1) The bispecific antibody DF00, which can use dual targeting to recruit T cells expressing PD-1 antigen to surrounding multiple myeloma cells with high BCMA expression, while suppressing the immunosuppressive microenvironment and remodeling T cells Cell killing of multiple myeloma cells. Background technique [0002] Tumor immunotherapy refers to the application of immunological principles and methods, by activating immune cells in the body and enhancing the body's anti-tumor immune response, specifically removing the minimal residual tumor lesions, inhibiting tumor growth, and breaking immune tolerance. Tumor immunotherapy is to overcome the mechanism of tumor immune escape, thereby reawakening i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/46C12N15/13A61K39/395A61P35/00A61P35/02
CPCC07K16/2878C07K16/2818A61P35/00A61P35/02C07K2317/31C07K2317/51C07K2317/515C07K2317/92C07K2317/73
Inventor 张娟李慧王阳王旻冯辉刘洪川
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com